A Comprehensive Review of Celecoxib Oral Solution for the Acute Treatment of Migraine
A migraine is a clinical diagnosis with a presentation of one or more severe unilateral or bilateral headache(s) often preceded by an aura and typically accompanied by nausea, vomiting, photophobia, and/or phonophobia. This neurological disease is often debilitating and greatly affects the quality of life of those it inflicts. In fact, a recent study conducted by the Global Burden of Disease and published in The Lancet Neurology revealed that migraines ranked second to only back pain as the most disabling disease. Triggers for migraines have ranged from female sex, low socioeconomic status, and diet to loud noises, sleep hygiene, and stress. Along with its clinical presentation, laboratory tests and imaging help rule out other potential causes of the headache and lead to a diagnosis of migraine. Migraines are typically divided into three phases: prodromal, headache, and postdrome. The pathophysiology of each phase remains under investigation, with differing theories regarding their pathways. Existing therapies are abortive therapies for acute migraines or preventative therapies. Abortive therapy consists of NSAIDs and triptans. Preventative therapies include tricyclic antidepressants, calcium channel blockers, beta-blockers, and anticonvulsants. In this review, we focus on the role of NSAIDs and the COX-2 inhibitor, celecoxib oral solution, for the abortive treatment of acute migraines.
1. Khan J, Asoom LIA, Sunni AA, et al. Genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine. Biomedicine & Pharmacotherapy. 2021;139:111557. doi:10.1016/j.biopha.2021.111557
2. Adams AM, Serrano D, Buse DC, et al. The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia. 2015;35(7):563-578. doi:10.1177/0333102414552532
3. Gross EC, Lisicki M, Fischer D, Sándor PS, Schoenen J. The metabolic face of migraine — from pathophysiology to treatment. Nat Rev Neurol. 2019;15(11):627-643. doi:10.1038/s41582-019-0255-4
4. Ong JJY, Wei DYT, Goadsby PJ. Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs. Drugs. 2018;78(4):411-437. doi:10.1007/s40265-018-0865-y
5. Kaube H, Katsarava Z, Przywara S, Drepper J, Ellrich J, Diener HC. Acute migraine headache. Neurology. 2002;58(8):1234-1238. doi:10.1212/wnl.58.8.1234
6. Ha H, Gonzalez A. Migraine headache prophylaxis. American Family Physician. 2019;99(1):17-24.
7. Lipton RB, Munjal S, Brand-Schieber E, Tepper SJ, Dodick DW. Efficacy, Tolerability, and Safety of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study. Headache. 2020;60(1):58-70. doi:10.1111/head.13663
8. Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache. 2021;61(1):60-68. doi:10.1111/head.14024
9. Burch RC, Buse DC, Lipton RB. Migraine: Epidemiology, Burden, and Comorbidity. Neurologic Clinics. 2019;37(4):631-649. doi:10.1016/j.ncl.2019.06.001
10. Stovner LJ, Nichols E, Steiner TJ, et al. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2018;17(11):954-976. doi:10.1016/s1474-4422(18)30322-3
11. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache. 2001;41(7):646-657. doi:10.1046/j.1526-4610.2001.041007646.x
12. Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. The Lancet Neurology. 2017;16(1):76-87. doi:10.1016/s1474-4422(16)30293-9
13. Lantéri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: A systematic review. Cephalalgia. 2011;31(7):837-850. doi:10.1177/0333102411398400
14. Buse DC, Scher AI, Dodick DW, et al. Impact of Migraine on the Family: Perspectives of People with Migraine and Their Spouse/Domestic Partner in the CaMEO Study. Mayo Clinic Proceedings. 2016;91(5):596-611. doi:10.1016/j.mayocp.2016.02.013
15. Lipton RB, Bigal ME. Migraine: Epidemiology, impact, and risk factors for progression. Headache. 2005;45(s1):S3-S13. doi:10.1111/j.1526-4610.2005.450101.x
16. Borkum JM. Migraine Triggers and Oxidative Stress: A Narrative Review and Synthesis. Headache. 2016;56(1):12-35. doi:10.1111/head.12725
17. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of Diagnosis and Acute and Preventive Treatment for Migraine in the United States: Results from the American Migraine Prevalence and Prevention Study. Headache. Published online November 17, 2006. doi:10.1111/j.1526-4610.2006.00631.x
18. Karsan N, Goadsby PJ. Biological insights from the premonitory symptoms of migraine. Nat Rev Neurol. 2018;14(12):41582-41018. doi:10.1038/s41582-018-0098-4
19. Schulte LH, Jürgens TP, May A. Photo-, osmo- and phonophobia in the premonitory phase of migraine: Mistaking symptoms for triggers? J Headache Pain. 2015;16(1). doi:10.1186/s10194-015-0495-7
20. Viana M, Sances G, Terrazzino S, Sprenger T, Nappi G, Tassorelli C. When cervical pain is actually migraine: An observational study in 207 patients. Cephalalgia. 2016;38(2):383-388. doi:10.1177/0333102416683917
21. Evans RW. Diagnostic Testing for Migraine and Other Primary Headaches. Neurologic Clinics. 2009;27(2):393-415. doi:10.1016/j.ncl.2008.11.009
22. Dodick DW. A Phase-by-Phase Review of Migraine Pathophysiology. Headache. 2018;58:4-16. doi:10.1111/head.13300
23. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017;97:553-622. doi:10.1152/physrev.00034.2015.-Plaguing
24. Puledda F, Messina R, Goadsby PJ. An update on migraine: Current understanding and future directions. J Neurol. 2017;264(9):00415-00017. doi:10.1007/s00415-017-8434-y
25. Goadsby PJ. Bench to bedside advances in the 21st century for primary headache disorders: Migraine treatments for migraine patients. Brain. 2016;139(10):2571-2577. doi:10.1093/brain/aww236
26. Puljak L, Marin A, Vrdoljak D, Markotic F, Utrobicic A, Tugwell P. Celecoxib for osteoarthritis. Cochrane Database of Systematic Reviews. 2017;2017(5). doi:10.1002/14651858.cd009865.pub2
27. Goldenberg MM. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clinical Therapeutics. 1999;21(9):1497-1513. doi:10.1016/s0149-2918(00)80005-3
28. Conaghan PG. A turbulent decade for NSAIDs: Update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int. 2012;32(6):1491. doi:10.1007/s00296-011-2263-6
29. Tindall E. Celecoxib for the treatment of pain and inflammation: The preclinical and clinical results - PubMed. J Am Osteopath. 1999;11 SupplS13-S17. https://pubmed.ncbi.nlm.nih.gov/10643176/
30. Zhang XY, Wei ZJ, Qiao WL, et al. Discovery of cyclooxygenase-2 inhibitors from Kadsura coccinea by affinity ultrafiltration mass spectrometry and the anti-inflammatory activity. Fitoterapia. 2021;151(104872):104872. doi:10.1016/j.fitote.2021.104872
31. Jelicic Kadic A, Fidahic M, Radic M, Puljak L. Celecoxib for rheumatoid arthritis. Cochrane Database of Systematic Reviews. Published online June 9, 2017. doi:10.1002/14651858.cd012095.pub2
32. Gong L, Thorn CF, Bertagnolli MM, Grosser T, Altman RB, Klein TE. Celecoxib pathways: Pharmacokinetics and pharmacodynamics. Pharmacogenetics and genomics. 2012;22(4):310-318. doi:10.1097/fpc.0b013e32834f94cb
33. Burian M, Geisslinger G. Klinische Pharmakologie der selektiven COX-2-Hemmer. Der Orthopäde. 2003;32(12):1078-1087. doi:10.1007/s00132-003-0569-0
34. Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib. Clinical Pharmacokinetics. 2000;38(3):225-242. doi:10.2165/00003088-200038030-00003
35. Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: A selective cyclo-oxygenase-2 inhibitor. Clinical Pharmacokinetics. 2000;38(3):225-242. doi:10.2165/00003088-200038030-00003
36. Paulson SK, Hribar JD, Liu NWK, et al. Metabolism and Excretion of [14C]Celecoxib in Healthy Male Volunteers. Drug Metabolism and Disposition. 2000;28(3).
37. Miller JL. Celecoxib approved as NSAID with some concessions on class warning. American Journal of Health-System Pharmacy. 1999;56(5):403-403. doi:10.1093/ajhp/56.5.403
38. Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: Systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther. 2005;7(3):R644-R665. doi:10.1186/ar1704
39. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial. Journal of Clinical Pharmacology. 2000;40(2):124-132. doi:10.1177/00912700022008766
40. Whelton A, Maurath CJ, Verburg KM, Geis GS. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. American Journal of Therapeutics. 2000;7(3):159-174. doi:10.1097/00045391-200007030-00004
41. Bensen WG, Fiechtner JJ, Mcmillen JI, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial. Mayo Clinic Proceedings. 1999;74(11):1095-1105. doi:10.4065/74.11.1095
42. Zhu XT, Chen L, Lin JH. Selective COX-2 inhibitor versus non-selective COX-2 inhibitor for the prevention of heterotopic ossification after total hip arthroplasty: A meta-analysis. Medicine. 2018;97(31):e11649. doi:10.1097/md.0000000000011649
43. Zhu Y, Zhang F, Chen W, Zhang Q, Liu S, Zhang Y. Incidence and risk factors for heterotopic ossification after total hip arthroplasty: A meta-analysis. Arch Orthop Trauma Surg. 2015;135(9):1307-1314. doi:10.1007/s00402-015-2277-8
44. Nauth A, Giles E, Potter BK, et al. Heterotopic ossification in orthopaedic trauma. Journal of Orthopaedic Trauma. 2012;26(12):684-688. doi:10.1097/bot.0b013e3182724624
45. Ma L, Zhang L, Wang H, Jiang C. Efficiency and safety: Comparison between preoperative analgesia and postoperative analgesia using non-steroidal anti-inflammatory drugs in patients receiving arthroscopic knee surgery in a multicenter, randomized, controlled study. Inflammopharmacol. 2021;29(3):651-659. doi:10.1007/s10787-021-00792-0
46. Saito T, Iwamoto S, Murotani K, et al. Efficacy of celecoxib as preemptive analgesia for patients undergoing laparoscopic inguinal hernia repair: A randomized trial. Surg Today. 2021;51(7):1118-1125. doi:10.1007/s00595-020-02199-w
47. Chirikov VV, Walker C, Stephens JM, et al. Evaluating the cost-effectiveness of celecoxib versus ibuprofen and naproxen in patients with osteoarthritis in united arab emirates based on the precision trial. CEOR. 2021;13:409-420. doi:10.2147/cdor.s280556
48. Hou J, Lin Y, Fang Y, et al. Clinical efficacy evaluation and prevention of adverse reactions in a randomized trial of a combination of three drugs in the treatment of cancerous pudendal neuralgia. Ann Palliat Med. 2021;10(5):5754-5762. doi:10.21037/apm-21-590
49. Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016;375(26):2519-2529. doi:10.1056/nejmoa1611593
50. Sgambati SA. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention: Commentary. Diseases of the Colon and Rectum. 2005;48(6):1331. doi:10.1056/nejmoa050405
51. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296(13):1633. doi:10.1001/jama.296.13.jrv60011
52. Hermann M, Ruschitzka F. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs. Annals of Medicine. 2007;39(1):18-27. doi:10.1080/0785389061073445
53. Kaplan-Machlis B, Klostermeyer BS. The cyclooxygenase-2 inhibitors: Safety and effectiveness. Ann Pharmacother. 1999;33(9):979-988. doi:10.1345/aph.18415
54. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial. JAMA. 1999;282(20):1921-1928. doi:10.1001/jama.282.20.1921
55. You JHS, Lee KKC, Chan TYK, Lau WH, Chan FKL. Arthritis treatment in Hong Kong - Cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents. Alimentary Pharmacology & Therapeutics. 2002;16(12):2089-2096. doi:10.1046/j.1365-2036.2002.01376.x
56. Fisher AA, Le Couteur DG. Intracerebral hemorrhage following possible interaction between celecoxib and clopidogrel. Ann Pharmacother. 2001;35(12):1567-1569. doi:10.1345/aph.1a110
57. Kaushik P, Zuckerman SJ, Campo NJ, Banda VR, Hayes SD, Kaushik R. Celecoxib-induced methemoglobinemia. Ann Pharmacother. 2004;38(10):1635-1638. doi:10.1345/aph.1e212
58. Peres MFP, Silberstein SD. Hemicrania Continua Responds to Cyclooxygenase-2 Inhibitors. Headache. 2002;42(6):530-531. doi:10.1046/j.1526-4610.2002.02131.x
59. Tan HJ, Teh HS, Raymond AA, Loo CY. Randomised, open label, controlled trial of celecoxib in the treatment of acute migraine. Singapore Medical Journal. 2007;48(9):834-839.
60. Rossi P, Tassorelli C, Allena M, Ferrante E, Lisotto C, Nappi G. Focus on therapy: Hemicrania continua and new daily persistent headache. The Journal of Headache and Pain. 2010;11(3):259-265. doi:10.1007/s10194-010-0194-3
61. Taghdiri F, Togha M, Razeghi Jahromi S, Paknejad SMH. Celecoxib vs prednisone for the treatment of withdrawal headache in patients with medication overuse headache: A randomized, double-blind clinical trial. Headache. 2015;55(1):128-135. doi:10.1111/head.12487
62. Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache. 2021;61(1):60-68. doi:10.1111/head.14024
63. Lipton RB, Munjal S, Brand-Schieber E, Tepper SJ, Dodick DW. Efficacy, Tolerability, and Safety of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study. Headache. 2020;60(1):58-70. doi:10.1111/head.13663
64. Gross EC, Lisicki M, Fischer D, Sándor PS, Schoenen J. The metabolic face of migraine — from pathophysiology to treatment. Nat Rev Neurol. 2019;15(11):627-643. doi:10.1038/s41582-019-0255-4